- Philstar.com
- The Philippine Star
- Pilipino Star Ngayon
- The Freeman
- Pang-Masa
- Banat
- Interaksyon
- Coupons
Array ( [results] => Array ( [0] => Array ( [ArticleID] => 1292902 [Title] => New Biologic Drug Is Targeted Treatment for Ovarian Cancer [Summary] =>Researchers have announced the development of a new biologic drug targeted to treat ovarian cancer. Its design could improve the treatment and survival statistics for some women suffering from this type of malignancy.
[DatePublished] => 2014-02-21 07:00:05 [ColumnID] => 0 [Focus] => 0 [AuthorID] => 1788586 [AuthorName] => Vonda J. Sines [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => http://img834.imageshack.us/img834/1294/46r7.jpg ) [1] => Array ( [ArticleID] => 850063 [Title] => Women urged to start pelvic exams at 40 [Summary] =>Women usually experience pelvic discomfort or bloating at different periods of their life. Increased abdominal girth that makes clothes fit tighter around the waist is a common condition that many women ignore, or just attribute to eating too much or aging.
[DatePublished] => 2012-09-18 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) [2] => Array ( [ArticleID] => 743585 [Title] => Roche launches drug for advanced ovarian cancer [Summary] =>Pharmaceutical company Roche recently launched an important milestone making its targeted therapy bevacizumab available for a disease where few treatment advances have been seen in over two decades.
[DatePublished] => 2011-11-03 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [3] => Array ( [ArticleID] => 742896 [Title] => First-line treatment for advanced ovarian cancer [Summary] =>Pharmaceutical company Roche recently launched an important milestone making its targeted therapy bevacizumab available for a disease where few treatment advances have been seen in over two decades.
[DatePublished] => 2011-11-01 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) [4] => Array ( [ArticleID] => 731565 [Title] => Treatment for advanced ovarian cancer receives positive opinion [Summary] =>BASEL, Switzerland — Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of bevacizumab in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer.
[DatePublished] => 2011-09-29 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [5] => Array ( [ArticleID] => 701306 [Title] => Researchers analyze gene changes in ovarian cancer [Summary] =>Researchers analyzing the genetic makeup of ovarian cancer tumors have found a gene mutation that is surprisingly frequent, suggesting it plays a key role in driving the cancer.
[DatePublished] => 2011-07-01 02:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => [SectionUrl] => [URL] => ) [6] => Array ( [ArticleID] => 696213 [Title] => Roche drug halves risk of disease worsening in women with recurrent ovarian cancer [Summary] =>Roche recently announced the results from OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of bevacizumab alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.
[DatePublished] => 2011-06-16 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [7] => Array ( [ArticleID] => 685871 [Title] => CA 125 plus ultrasound detects early ovarian ca [Summary] =>Large-scale screening for ovarian cancer with a combination of transvaginal ultrasound and cancer antigen 125 is a feasible strategy that can accurately identify early cancers, a large UK trial of almost 203,000 women concluded.
[DatePublished] => 2011-05-15 00:00:00 [ColumnID] => 136231 [Focus] => 0 [AuthorID] => 1805110 [AuthorName] => Charles C. Chante MD [SectionName] => Opinion [SectionUrl] => opinion [URL] => ) [8] => Array ( [ArticleID] => 676897 [Title] => IVF regimen linked to ovarian cancer risk [Summary] =>Ovarian stimulation for in vitro fertilization was linked to an increased risk of ovarian cancer 15 years later in a large cohort study that followed thousands of women in the Netherlands.
[DatePublished] => 2011-04-17 00:00:00 [ColumnID] => 136231 [Focus] => 0 [AuthorID] => 1805110 [AuthorName] => Charles C. Chante MD [SectionName] => Opinion [SectionUrl] => opinion [URL] => ) [9] => Array ( [ArticleID] => 657719 [Title] => Treatment helps women with ovarian cancer live significantly longer [Summary] =>Roche announced this week that OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of bevacizumab alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.
[DatePublished] => 2011-02-17 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
OVARIAN
Array ( [results] => Array ( [0] => Array ( [ArticleID] => 1292902 [Title] => New Biologic Drug Is Targeted Treatment for Ovarian Cancer [Summary] =>Researchers have announced the development of a new biologic drug targeted to treat ovarian cancer. Its design could improve the treatment and survival statistics for some women suffering from this type of malignancy.
[DatePublished] => 2014-02-21 07:00:05 [ColumnID] => 0 [Focus] => 0 [AuthorID] => 1788586 [AuthorName] => Vonda J. Sines [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => http://img834.imageshack.us/img834/1294/46r7.jpg ) [1] => Array ( [ArticleID] => 850063 [Title] => Women urged to start pelvic exams at 40 [Summary] =>Women usually experience pelvic discomfort or bloating at different periods of their life. Increased abdominal girth that makes clothes fit tighter around the waist is a common condition that many women ignore, or just attribute to eating too much or aging.
[DatePublished] => 2012-09-18 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) [2] => Array ( [ArticleID] => 743585 [Title] => Roche launches drug for advanced ovarian cancer [Summary] =>Pharmaceutical company Roche recently launched an important milestone making its targeted therapy bevacizumab available for a disease where few treatment advances have been seen in over two decades.
[DatePublished] => 2011-11-03 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [3] => Array ( [ArticleID] => 742896 [Title] => First-line treatment for advanced ovarian cancer [Summary] =>Pharmaceutical company Roche recently launched an important milestone making its targeted therapy bevacizumab available for a disease where few treatment advances have been seen in over two decades.
[DatePublished] => 2011-11-01 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) [4] => Array ( [ArticleID] => 731565 [Title] => Treatment for advanced ovarian cancer receives positive opinion [Summary] =>BASEL, Switzerland — Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of bevacizumab in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer.
[DatePublished] => 2011-09-29 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [5] => Array ( [ArticleID] => 701306 [Title] => Researchers analyze gene changes in ovarian cancer [Summary] =>Researchers analyzing the genetic makeup of ovarian cancer tumors have found a gene mutation that is surprisingly frequent, suggesting it plays a key role in driving the cancer.
[DatePublished] => 2011-07-01 02:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => [SectionUrl] => [URL] => ) [6] => Array ( [ArticleID] => 696213 [Title] => Roche drug halves risk of disease worsening in women with recurrent ovarian cancer [Summary] =>Roche recently announced the results from OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of bevacizumab alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.
[DatePublished] => 2011-06-16 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [7] => Array ( [ArticleID] => 685871 [Title] => CA 125 plus ultrasound detects early ovarian ca [Summary] =>Large-scale screening for ovarian cancer with a combination of transvaginal ultrasound and cancer antigen 125 is a feasible strategy that can accurately identify early cancers, a large UK trial of almost 203,000 women concluded.
[DatePublished] => 2011-05-15 00:00:00 [ColumnID] => 136231 [Focus] => 0 [AuthorID] => 1805110 [AuthorName] => Charles C. Chante MD [SectionName] => Opinion [SectionUrl] => opinion [URL] => ) [8] => Array ( [ArticleID] => 676897 [Title] => IVF regimen linked to ovarian cancer risk [Summary] =>Ovarian stimulation for in vitro fertilization was linked to an increased risk of ovarian cancer 15 years later in a large cohort study that followed thousands of women in the Netherlands.
[DatePublished] => 2011-04-17 00:00:00 [ColumnID] => 136231 [Focus] => 0 [AuthorID] => 1805110 [AuthorName] => Charles C. Chante MD [SectionName] => Opinion [SectionUrl] => opinion [URL] => ) [9] => Array ( [ArticleID] => 657719 [Title] => Treatment helps women with ovarian cancer live significantly longer [Summary] =>Roche announced this week that OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of bevacizumab alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.
[DatePublished] => 2011-02-17 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
abtest
EZ2/LVM - 6 9
SUERTRES - 2 6 6
4D Lotto - 8 4 0 3
6/45 Mega Lotto - 36 45 35 20 12 3
P88,642,614.00
6/55 Grand Lotto - 55 9 2 21 26 8
P36,795,367.00
- 12:00 am